Overview

Trial of PDE4 Inhibition With Roflumilast for the Management of Seborrheic Dermatitis (STRATUM)

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The study will assess the safety and efficacy of ARQ-154 foam vs vehicle applied once for 8 weeks by subjects with seborrheic dermatitis.
Phase:
Phase 3
Details
Lead Sponsor:
Arcutis Biotherapeutics, Inc.